Benzinga Money is a reader-supported publication. We may earn a commission from the advertisers associated with this article. Read our Advertiser Discloser.
Despite heart disease being the leading cause of death worldwide, one of the most common early detection tools has a fundamental flaw. An electrocardiogram, sometimes called an ECG or EKG, is used to measure the heart’s electrical activity to detect any rhythm-related issues, like arrhythmia or AFib.
The problem? The ECG doesn’t detect other issues such as restricted blood flow to the heart or irregular heart rhythms, which if left untreated could cause severe or life-threatening complications.
One company believes they’ve found the solution, and now you can join them to help bring earlier detection to people across the globe.
HeartSciences has developed an AI-ECG that’s being trialed in some of the country’s top cardiology facilities to better diagnose and treat heart conditions that can go undetected by traditional devices.
The company has broad patents covering its technology. With Mayo Clinic as an early AI-ECG adopter and Medicare reimbursement already starting in January 2025, nowʼs your chance to invest before FDA submission and full-scale commercialization begins.
A $32B Opportunity
More than 1 billion ECGs are administered annually worldwide, and the global ECG market is projected to reach $32B by 2034. As a result, healthcare systems will search for more advanced and accurate diagnostic tools, like HeartSciences MyoVista technology.
Their solution is rooted in AI-ECG algorithms developed using advanced convolutional neural networks (CNN), deep learning techniques, which are often trained on more than 120,000 ECG records. For example, its aortic stenosis algorithm, which has received FDA Breakthrough Device designation, has been shown in published data to detect aortic stenosis up to 24 months prior to traditional ECGs, and its diagnostic accuracy increased as the disease progressed.
Aortic stenosis is a condition in which your valve narrows, resulting in restricted blood flow to the rest of the body.
Other algorithms include those to detect a weak heart pump or early stage cardiac dysfunction which is not possible using traditional ECGs, many heart disease patients are asymptomatic or the symptoms are so mild — such as fatigue and chest pains — that they are not recognized as a more serious condition, leading to delays in treatment and a higher risk of life-threatening complications.
Once these algorithms are cleared by the FDA, health systems and hospitals could utilize HeartSciences’ MyoVista Insights cloud-based platform to check for heart disease much earlier and more cost effectively. The cloud software system could be integrated with existing ECG devices.
HeartSciences’ AI-ECG technology offers three key clinical advantages to diagnosing and treating heart disease:
- Detection in asymptomatic or under-evaluated patients who may not yet show signs of disease.
- Real-time or retrospective analysis using existing ECG data already captured during routine care.
- Expanded access to early diagnosis, especially in underserved areas lacking specialized cardiac imaging or providers.
Trusted by Top Healthcare Systems Worldwide
HeartSciences’ algorithm and technology have been developed with some of the top cardiology facilities and systems in the world, including Mount Sinai in NY and Rutgers University Hospital.
Beta use and key opinion leader engagement have already started in the UK, Denmark, Australia, India, and Ireland.
Additionally, CPT codes for AI-ECG are already in place, Medicare reimbursement for the technology began in January 2025, and HeartSciences is expected to receive FDA approvals and be in revenue in 2026.
Each $3.50 unit includes one convertible preferred share and one warrant to purchase an additional share of common stock. That’s two potential shares of Nasdaq tradeable common stock equity per unit, with the added benefit of preferred stock protections until you want to convert and timing flexibility on the warrant. It’s an investment structure often reserved for institutional insiders—but available to everyday investors in this offering.
HeartSciences has been rated a “Strong Buy” on Yahoo Finance, with the average analyst price 1-year target being over 500% potential upside to a $3.50 investment unit price.
An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement, which only means that the company may make sales of the securities described by the offering statement. Additional information on the company and risk factors related to the offering can be found in the offering circular that is part of that offering statement and is available here.
This Regulation A+ offering is made available through Digital Offering, LLC. This investment is speculative, potentially illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Disclaimers
Please be advised that alternative investments carry a risk of monetary loss. Neither Benzinga nor its staff recommends that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. All information contained on this website is provided as general commentary for informative and entertainment purposes and does not constitute investment advice.
Benzinga will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on this information, whether specifically stated in the above Terms of Service or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
